Larazotide Protocol — Complete Dosing & Administration Guide

Dosing

How muchdo I take?

Oral: Taken by mouth as a capsule, tablet, or liquid.

Bioavailability Varies by compound — many peptides are largely broken down in the gut, so little reaches the blood intact; some small molecules absorb well.

Standard Dose

0.5 mg

Frequency

Three times daily (before meals)

Duration

12 weeks in trials; ongoing for symptom control

Trial-established dose: in a Phase 2b randomized controlled trial in celiac disease, 0.5 mg three times daily met the primary endpoint with fewer symptoms vs placebo. Notably, the higher 1 mg and 2 mg doses showed no benefit over placebo, so 0.5 mg is the effective dose [6]. Taken before meals as a local intestinal tight-junction regulator [1].

Timing

Best time to take

Take Larazotide at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.

With food?

Larazotide can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.

If stacking

Larazotide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting Your Dose

Increase if

+You've tolerated the current dose for the recommended period without significant side effects

+Therapeutic goals haven't been met at the current dose level

+Your healthcare provider recommends dose escalation based on your response

+Lab work or clinical assessments support a higher dose

Decrease if

-Side effects are bothersome or impacting daily life despite management strategies

-You experience any signs of an adverse reaction

-Lab results indicate the need for dose reduction

-Your healthcare provider recommends a lower dose based on your response

Signs of right dose

✓Therapeutic goals being met with minimal side effects

✓Stable and consistent response to treatment

✓Lab values or clinical markers trending in the right direction

✓Good tolerance with manageable or absent side effects

Dosing Calculator

Calculate Your Exact Dose

Step 1: Peptide Weight

Find the weight printed on your peptide vial label

Look here!

The peptide weight is printed on the label

The weight is on the label

Select Weight

Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)

Administration

How do Iuse it?

Reconstitution

What you need

•Larazotide in its prescribed form

•Clean, dry storage container

•Measuring device if applicable (oral syringe, measuring cup)

•Calendar or reminder app for dosing schedule

Example

Larazotide comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.

Use Larazotide exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.

Injection

Route

Larazotide is administered Oral (capsule or tablet)—no injection required

Best sites

•Not applicable—this is not an injectable formulation

Technique

1.Follow the specific administration instructions for your Larazotide formulation

2.Take or apply as directed by your healthcare provider

3.Store properly between uses according to package instructions

Storage

Before reconstitution

Store Larazotide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, Larazotide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation

Solution appears cloudy, discolored, or contains visible particles (should be clear)

Product has been exposed to temperatures outside the recommended storage range

Product has been frozen (unless specifically designed for freeze-thaw stability)

Expiration date has passed or reconstituted solution has exceeded its use-by date

Unusual odor, color change, or visible contamination

Sample Daily Schedule

As prescribed (once daily)

As prescribed by your healthcare provider injection

Site: Oral (capsule or tablet)—rotate sites if applicable

Maintain a consistent schedule for optimal results with Larazotide. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is itsafe?

Safety Profile

Larazotide (ALX-0061, AT-1001) is a synthetic tight-junction regulator that improved intestinal barrier function in Phase 2 celiac disease trials with favorable safety. The mechanism—zonula occludens-1 modulation—is specific to epithelial tight junctions without broad immunosuppression. Gastrointestinal side effects (nausea, diarrhea, abdominal pain) occur in 10-20% of patients but are typically mild and resolve with dose adjustment or continued exposure. FDA feedback on Phase 3 trials indicated efficacy trends but required additional manufacturing and clinical data before approval consideration.

Larazotide safety derives from two Phase 2b randomized controlled trials (n=316 and n=362 patients) published in Gut and Gastroenterology showing no serious adverse events attributable to larazotide and favorable tolerability compared to placebo. Serum enzyme elevation was minimal and reversible. Phase 3 trial data remain unpublished as of 2025, but regulatory interactions with FDA suggest development is ongoing. The peptide demonstrates selective intestinal barrier modulation without systemic toxicity in evaluated cohorts.

Common Side Effects

Experienced by some users

Headache

Occasional headaches reported in clinical trials, usually mild and transient. Often resolves within a few hours to days.

Management: Stay hydrated, rest in a quiet environment, and monitor frequency. If persistent, discuss with your healthcare provider about dose adjustment.

Nausea

Some patients experience mild nausea, particularly when taking the peptide on an empty stomach. This is typically mild and temporary.

Management: Take larazotide with food or a light meal to minimize nausea. Try ginger tea or small frequent meals throughout the day.

Abdominal Cramping

Occasional mild cramping or discomfort reported during the adjustment period. Usually diminishes after the first week of treatment.

Management: Use a heating pad, practice gentle stretching, and ensure adequate hydration. Contact your doctor if cramping is severe or persistent.

Fatigue

Rare reports of mild fatigue, possibly related to the body's healing response. Energy levels typically normalize quickly.

Management: Ensure adequate sleep, maintain good nutrition, and stay physically active. Supplement with B vitamins if deficient.

Less Common

•Transient Diarrhea

These typically resolve with continued use or dose adjustment.

Stop and Seek Help If

×Severe or worsening side effects that don't improve with dose adjustment or supportive care

×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing

×Your healthcare provider recommends discontinuation based on your clinical response

×Development of any new medical condition that may be contraindicated with Larazotide

×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)

×Abnormal lab results or clinical markers that suggest adverse effects

Larazotide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Interactions

With other peptides

✓Synergistic intestinal barrier repair - glutamine feeds enterocytes while larazotide regulates tight junctions

✓Supports healthy gut microbiome while larazotide restores barrier function for better probiotic colonization

✓Essential for tight junction protein synthesis and intestinal epithelial cell repair

With medications

!High-dose NSAIDs - Can increase intestinal permeability and may counteract larazotide's barrier-protective effects

!Excessive Alcohol - Alcohol damages tight junctions and can undermine larazotide's therapeutic benefits

!Certain Antibiotics - May disrupt beneficial gut microbiota needed for barrier healing synergy

With supplements

✓Multivitamins - Generally safe to take alongside Larazotide. Space doses apart if taking oral formulations to ensure optimal absorption.

✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Want the Full Picture?

View the complete Larazotide research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.